Blinatumoab公司
医学
淋巴细胞白血病
肿瘤科
重症监护医学
白血病
内科学
作者
Naresh Bumma,Nikolaos Papadantonakis,Anjali S. Advani
出处
期刊:Future Oncology
[Future Medicine]
日期:2015-06-01
卷期号:11 (12): 1729-1739
被引量:12
摘要
The treatment of acute lymphoblastic leukemia (ALL) in adults remains challenging and novel therapies are needed. The antigen, CD19, is expressed by >90% of pre-B ALLs and represents an attractive therapeutic target. The bispecific T-cell-engaging antibody, blinatumomab, targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL. In this review, we discuss in detail the mechanism of action and key pharmacologic aspects of blinatumomab. In addition, the preclinical studies, clinical studies and toxicities are summarized.
科研通智能强力驱动
Strongly Powered by AbleSci AI